C9orf72 repeat transcripts undergo non-ATG translation producing DPRs (poly-GA, poly-GR, poly-PR) that sequester nucleocytoplasmic transport factors (RanGAP1, NUP205, TPR), causing nuclear envelope rupture and transport impairment. This represents the most mechanistically detailed hypothesis for C9orf72-ALS/FTD, with compelling evidence from multiple laboratories and promising therapeutic candidates (KPT-276, importin-β agonists). However, causality remains debated—DPR accumulation may be a consequence rather than driver. The hypothesis faces challenges from variable DPR-disease severity correlation and multiple parallel pathogenic mechanisms (C9orf72 haploinsufficiency, RNA foci, tidal RNAs).
...
C9orf72 repeat transcripts undergo non-ATG translation producing DPRs (poly-GA, poly-GR, poly-PR) that sequester nucleocytoplasmic transport factors (RanGAP1, NUP205, TPR), causing nuclear envelope rupture and transport impairment. This represents the most mechanistically detailed hypothesis for C9orf72-ALS/FTD, with compelling evidence from multiple laboratories and promising therapeutic candidates (KPT-276, importin-β agonists). However, causality remains debated—DPR accumulation may be a consequence rather than driver. The hypothesis faces challenges from variable DPR-disease severity correlation and multiple parallel pathogenic mechanisms (C9orf72 haploinsufficiency, RNA foci, tidal RNAs). The Skeptic revised confidence to 0.72, noting that poly-GA inclusions show minimal correlation with disease severity.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["C9orf72 Hexanucleotide Repeat Expansion"]
B["Dipeptide Repeat Proteins Poly-GA-PA-PR-Pro"]
C["NUP98 Nuclear Pore Impairment"]
D["Nucleocytoplasmic Transport Blocked"]
E["mRNA Export Deficit"]
F["Proteostatic Stress and Aggregation"]
G["NUP98 as Therapeutic Target"]
A --> B
B --> C
C --> D
D --> E
E --> F
F --> G
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
8 citations3 with PMIDValidation: 0%4 supporting / 4 opposing
✓For(4)
No supporting evidence
No opposing evidence
(4)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
6
1
1
MECH 6CLIN 1GENE 1EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
DPRs disrupt nuclear import in cellular models; PM…
Transportin mislocalization in patient neurons; PMID related
✗ Opposing Evidence
4
DPR toxicity does not consistently correlate with expansion size or disease severity
KPT-276 has multiple cellular targets; rescue may be indirect
Variable penetrance in monozygotic twins suggests modifiers beyond DPR
Alternative mechanisms (C9orf72 LOF, RNA foci) may drive pathology independently
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-26 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Legacy Pre-Pipeline Hypotheses: Neurodegeneration
Hypothesis 1: Exosomal α-Synuclein as an Interneuronal Propagation Vector in Parkinson's Disease
Mechanism: Misfolded α-synuclein (aSyn) aggregates are transmitted via exosomes from donor to recipient neurons, templating endogenous aSyn misfolding through a "prion-like" mechanism. This explains the stereotypical progression of Lewy pathology in Braak staging.
This assessment evaluates each hypothesis across five critical domains using a standardized framework. Evidence strength, translational readiness, and development feasibility are rated on consistent scales to enable cross-hypothesis comparison. Where the Skeptic's revised confidence scores diverge from my independent assessment, I note the discrepancy and rationale.
IF C9orf72-ALS patient-derived motor neurons are treated with antisense oligonucleotides that selectively reduce DPR protein levels (poly-GA, poly-GR, poly-PR) without altering C9orf72 mRNA or RNA foci burden, THEN nucleocytoplasmic transport will significantly normalize (assessed by nuclear import rate of NLS-mCherry reporter) within 3 weeks post-treatment compared to scramble control-treated neurons.
pendingconf: 0.65
Expected outcome: Nuclear import rate will increase by ≥40% in DPR-reduced neurons relative to baseline, with no change in total C9orf72 transcript levels
Falsified by: Nuclear import rate remains impaired (no significant change) despite ≥70% reduction in DPR levels, indicating DPR accumulation is a downstream consequence rather than driver of transport dysfunction
Method: iPSC-derived motor neurons from at least 3 C9orf72-ALS patients (lines with high DPR burden confirmed by immunostaining); treatment with repeat-directed ASOs (targeting upstream ORF orstart codon of each DPR frame); live-cell imaging of NLS-mCherry nuclear accumulation over 30 minutes using confocal microscopy
IF we stratify C9orf72-ALS/FTD patients by cerebrospinal fluid DPR levels (poly-GR top quartile vs. bottom quartile) at baseline, THEN the high DPR group will exhibit significantly greater impairment of nuclear export (assessed by nuclear/cytoplasmic ratio of hnRNP A1 in peripheral blood lymphocytes) compared to the low DPR group at 6-month follow-up.
pendingconf: 0.58
Expected outcome: High DPR group will show ≥35% higher nuclear hnRNP A1 accumulation (indicating export impairment) compared to low DPR group, with correlation strength r ≥ 0.5 between CSF DPR levels and nuclear transport defect
Falsified by: No significant difference in nuclear export markers between high and low DPR quartiles (p > 0.05), or inverse correlation between DPR burden and transport impairment, disproving DPRs as causal mediators of transport dysfunction
Method: Prospective cohort study of 80 C9orf72-ALS/FTD patients (40 confirmed hexanucleotide repeat carriers) with lumbar puncture at baseline and 6 months; ELISA quantification of CSF poly-GR and poly-GA levels; immunofluorescence microscopy of hnRNP A1 localization in isolated lymphocytes
Knowledge Subgraph (0 edges)
No knowledge graph edges recorded
3D Protein Structure
🧬
NUP98 — Search for structure
Click to search RCSB PDB